Project description
Dermatological cream for the topical treatment of skin ulcers
Acute and chronic skin ulcers, such as diabetic foot ulcers, pressure ulcers and leg ulcers, dramatically decrease the quality of life in affected patients, and currently available therapeutic procedures have low efficacy. The EU-funded LYSADERM project aims to develop the first medicinal cream containing platelet lysate (PL) that can be used for the topical therapy of skin ulcers. Platelets have demonstrated their potential in enhancing the healing of skin, muscles, tendons and ligaments as the growth factors released by platelets recruit reparative cells. Phase I of the project will evaluate the technical feasibility and economic viability of the product development.
Objective
The LYSADERM project aims at the fabrication of a medicinal cream containing Platelet Lysate (PL), that can be used for the topical therapy of skin ulcers. The applicant company Episkey is an innovative start-up founded in 2016 with the aim of introducing into the market novel therapeutic products obtained from human Platelet Lysate. Episkey holds the exclusive licenses of international patents covering the therapeutic administration of cord blood Platelet Lysate, and already developed an international network of cord blood banks aimed at the procurement of Cord Blood Platelet Lysate for pharmaceutical transformation into platelet derivatives and drugs. Within the broad scope of our company mission, the LYSADERM project aims at marketing a novel formulation of dermatological cream containing tissue regenerative factors present in human platelets. The LYSADERM dermatological cream will be therefore used for the treatment of skin ulcers, including serious disorders, such as diabetic foot ulcers, pressure ulcers and leg ulcers. LYSADERM aims to be the first pharmaceutical cream containing Platelet Lysate, and it is expected to improve healing of the ulcers in comparison to conventional treatments, at lower cost; therefore, it would become the standard procedure to treat diabetic foot ulcers, pressure ulcers and leg ulcers. The LYSADERM business project is expected to generate positive outcomes for the whole society, such as the increase of effectiveness in the treatment of skin ulcers both in hospitals and at the patient’s home. It is roughly estimated that once industrialized, LYSADERM can generate in just 5 years a total of over 10 M annual revenues, covering the 0.4% of the EU market share. Overall, the main objective of our phase I project is to achieve the technical definition of the LYSADERM product, to realize a complete exploitation plan, and to consolidate our business plan through a second-level FTO and the definition of the financial forecasts.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences clinical medicine endocrinology diabetes
- social sciences economics and business business and management business models
- medical and health sciences medical biotechnology cells technologies stem cells
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
20121 MILANO
Italy
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.